Physician profile
David Sanchez
NPI 1528001260
$1,831.67
in general payments reported to CMS, 2019-2025
22 companies · $262 in 2025
The $262 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $128 · 2021: $215 · 2022: $244 · 2023: $290 · 2024: $247 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $368.94 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Glaxosmithkline, LLC. | $302.60 | 2019-2025 | Bexsero |
| Pfizer INC. | $169.40 | 2019-2025 | |
| Cranial Technologies, INC | $166.34 | 2020-2025 | Doc Band |
| Genzyme Corporation | $130.47 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $114.45 | 2022 | |
| Sanofi Pasteur INC. | $99.84 | 2019-2025 | |
| Biomarin Pharmaceutical INC. | $76.76 | 2022-2024 | Voxzogo 1.2mg |
| Sobi, INC | $45.42 | 2019-2021 | |
| Alk-Abello, INC | $42.97 | 2024-2025 | Ragwitek, Grastek, Odactra |
| Shield Therapeutics INC | $38.27 | 2023-2024 | Accrufer |
| Abbott Laboratories | $33.79 | 2021-2024 | Freestyle Libre 3 |
| Phadia US INC. | $32.67 | 2025 | Immunocap |
| Cipher Pharmaceuticals US LLC | $32.46 | 2025 | Natroba, Spinosad |
| Novartis Pharmaceuticals Corporation | $31.14 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $30.14 | 2024 | Kristalose |
| Takeda Pharmaceuticals U.S.A., INC. | $24.02 | 2024 | |
| Alexion Pharmaceuticals, INC. | $23.51 | 2025 | Koselugo |
| Oxford Immunotec USA INC | $21.17 | 2022 | |
| Novo Nordisk INC | $18.17 | 2025 | Ozempic |
| Ironwood Pharmaceuticals, INC | $15.18 | 2024 | |
| Aytu Biopharma, INC. | $13.96 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.